Dendritic cell-based vaccines: barriers and opportunities

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Koski GK, Cohen PA, Roses RE, Xu S, Czerniecki BJ. Reengineering dendritic cell-based anti-cancer vaccines. Immunol. Rev.222,256–276 (2008).
  Medline CASGoogle Scholar
• 2  Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu. Rev. Immunol.18,245–273 (2000).
  Medline CASGoogle Scholar
• 3  Inaba K, Romani N, Steinman RM. An antigen-independent contact mechanism as an early step in T cell-proliferative responses to dendritic cells. J. Exp. Med.170(2),527–542 (1989).
  Medline CASGoogle Scholar
• 4  Ludewig B, Oehen S, Barchiesi F, Schwendener RA, Hengartner H, Zinkernagel RM. Protective antiviral cytotoxic T cell memory is most efficiently maintained by restimulation via dendritic cells. J. Immunol.163(4),1839–1844 (1999).
  Medline CASGoogle Scholar
• 5  Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med.1(12),1297–1302 (1995).
  Medline CASGoogle Scholar
• 6  Mehta-Damani A, Markowicz S, Engleman EG. Generation of antigen-specific CD8⁺ CTLs from naive precursors. J. Immunol.153(3),996–1003 (1994).
  Medline CASGoogle Scholar
• 7  Mehta-Damani A, Markowicz S, Engleman EG. Generation of antigen-specific CD4⁺ T cell lines from naive precursors. Eur. J. Immunol.25(5),1206–1211 (1995).
  Medline CASGoogle Scholar
• 8  Guery JC, Ria F, Adorini L. Dendritic cells but not B cells present antigenic complexes to class II-restricted T cells after administration of protein in adjuvant. J. Exp. Med.183(3),751–757 (1996).
  Medline CASGoogle Scholar
• 9  Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med.183(1),283–287 (1996).
  Medline CASGoogle Scholar
• 10  Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med.183(1),317–322 (1996).
  Medline CASGoogle Scholar
• 11  Flamand V, Sornasse T, Thielemans K et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur. J. Immunol.24(3),605–610 (1994).
  Medline CASGoogle Scholar
• 12  Sancho D, Mourao-Sa D, Joffre OP et al. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J. Clin. Invest.118(6),2098–2110 (2008).
  Medline CASGoogle Scholar
• 13  Lanzavecchia A. Mechanisms of antigen uptake for presentation. Curr. Opin Immunol.8(3),348–354 (1996).
  Medline CASGoogle Scholar
• 14  Norbury CC, Chambers BJ, Prescott AR, Ljunggren HG, Watts C. Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells. Eur. J. Immunol.27(1),280–288 (1997).
  Medline CASGoogle Scholar
• 15  Albert ML, Pearce SF, Francisco LM et al. Immature dendritic cells phagocytose apoptotic cells via αvβ5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med.188(7),1359–1368 (1998).
  Medline CASGoogle Scholar
• 16  Shen Z, Reznikoff G, Dranoff G, Rock KL. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J. Immunol.158(6),2723–2730 (1997).
  Medline CASGoogle Scholar
• 17  Pooley JL, Heath WR, Shortman K. Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8^- dendritic cells, but cross-presented to CD8 T cells by CD8⁺ dendritic cells. J. Immunol.166(9),5327–5330 (2001).
  Medline CASGoogle Scholar
• 18  Zitvogel L, Regnault A, Lozier A et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat. Med.4(5),594–600 (1998).
  Medline CASGoogle Scholar
• 19  Chandawarkar RY, Wagh MS, Srivastava PK. The dual nature of specific immunological activity of tumor-derived gp96 preparations. J. Exp. Med.189(9),1437–1442 (1999).
  Medline CASGoogle Scholar
• 20  Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science264(5161),961–965 (1994).
  Medline CASGoogle Scholar
• 21  Heath WR, Carbone FR. Cross-presentation in viral immunity and self-tolerance. Nat. Rev. Immunol.1(2),126–134 (2001).
  Medline CASGoogle Scholar
• 22  Kreer C, Rauen J, Zehner M, Burgdorf S. Cross-presentation: how to get there – or how to get the ER. Front. Immunol.2,87 (2011).▪ Reviews various mechanisms underlying cross-presentation in dendritic cells (DCs) highlighting both the complexity and diversity of these cellular pathways and pointing out new research directions for understanding this important capability.
  MedlineGoogle Scholar
• 23  Delamarre L, Pack M, Chang H, Mellman I, Trombetta ES. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science307(5715),1630–1634 (2005).
  Medline CASGoogle Scholar
• 24  Savina A, Jancic C, Hugues S et al. NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell126(1),205–218 (2006).
  Medline CASGoogle Scholar
• 25  Mantegazza AR, Savina A, Vermeulen M et al. NADPH oxidase controls phagosomal pH and antigen cross-presentation in human dendritic cells. Blood112(12),4712–4722 (2008).
  Medline CASGoogle Scholar
• 26  Hotta C, Fujimaki H, Yoshinari M, Nakazawa M, Minami M. The delivery of an antigen from the endocytic compartment into the cytosol for cross-presentation is restricted to early immature dendritic cells. Immunology117(1),97–107 (2006).
  Medline CASGoogle Scholar
• 27  Dudziak D, Kamphorst AO, Heidkamp GF et al. Differential antigen processing by dendritic cell subsets in vivo. Science315(5808),107–111 (2007).
  Medline CASGoogle Scholar
• 28  Bonifaz LC, Bonnyay DP, Charalambous A et al.In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med.199(6),815–824 (2004).
  Medline CASGoogle Scholar
• 29  Tsuji T, Matsuzaki J, Kelly MP et al. Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8⁺ and CD4⁺ T cell responses with broad antigen specificity. J. Immunol.186(2),1218–1227 (2011).
  Medline CASGoogle Scholar
• 30  Burgdorf S, Kautz A, Bohnert V, Knolle PA, Kurts C. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science316(5824),612–616 (2007).
  Medline CASGoogle Scholar
• 31  Weck MM, Appel S, Werth D et al. hDectin-1 is involved in uptake and cross-presentation of cellular antigens. Blood111(8),4264–4272 (2008).
  Medline CASGoogle Scholar
• 32  Baker K, Qiao SW, Kuo TT et al. Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8^-CD11b⁺ dendritic cells. Proc. Natl Acad. Sci. USA108(24),9927–9932 (2011).
  Medline CASGoogle Scholar
• 33  Chatterjee B, Smed-Sorensen A, Cohn L et al. Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells. Blood120(10),2011–2020 (2012).
  Medline CASGoogle Scholar
• 34  Idoyaga J, Lubkin A, Fiorese C et al. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to langerin, DEC205, and Clec9A. Proc Natl Acad. Sci. USA108(6),2384–2389 (2011).
  Medline CASGoogle Scholar
• 35  Klechevsky E, Flamar AL, Cao Y et al. Cross-priming CD8⁺ T cells by targeting antigens to human dendritic cells through DCIR. Blood116(10),1685–1697 (2010).
  Medline CASGoogle Scholar
• 36  Tacken PJ, Ginter W, Berod L et al. Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation. Blood118(15),4111–4119 (2011).
  Medline CASGoogle Scholar
• 37  Burgdorf S, Scholz C, Kautz A, Tampe R, Kurts C. Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat. Immunol.9(5),558–566 (2008).
  Medline CASGoogle Scholar
• 38  Ackerman AL, Giodini A, Cresswell P. A role for the endoplasmic reticulum protein retrotranslocation machinery during crosspresentation by dendritic cells. Immunity25(4),607–617 (2006).
  Medline CASGoogle Scholar
• 39  Ackerman AL, Kyritsis C, Tampe R, Cresswell P. Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens. Proc. Natl Acad. Sci. USA100(22),12889–12894 (2003).
  Medline CASGoogle Scholar
• 40  Kovacsovics-Bankowski M, Rock KL. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science267(5195),243–246 (1995).
  Medline CASGoogle Scholar
• 41  Rock KL, Shen L. Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol. Rev.207,166–183 (2005).
  Medline CASGoogle Scholar
• 42  Young JW, Steinman RM. Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4⁺ helper T cells. J. Exp. Med.171(4),1315–1332 (1990).
  Medline CASGoogle Scholar
• 43  Bhardwaj N, Bender A, Gonzalez N, Bui LK, Garrett MC, Steinman RM. Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8⁺ T cells. J. Clin. Invest.94(2),797–807 (1994).
  Medline CASGoogle Scholar
• 44  Liu YJ, Kanzler H, Soumelis V, Gilliet M. Dendritic cell lineage, plasticity and cross-regulation. Nat. Immunol.2(7),585–589 (2001).
  Medline CASGoogle Scholar
• 45  Pulendran B, Smith JL, Caspary G et al. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc. Natl Acad. Sci. USA96(3),1036–1041 (1999).
  Medline CASGoogle Scholar
• 46  Maldonado-Lopez R, De Smedt T, Michel P et al. CD8α⁺ and CD8α^- subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J. Exp. Med.189(3),587–592 (1999).
  Medline CASGoogle Scholar
• 47  den Haan JM, Lehar SM, Bevan MJ. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med.192(12),1685–1696 (2000).
  Medline CASGoogle Scholar
• 48  Schnorrer P, Behrens GM, Wilson NS et al. The dominant role of CD8⁺ dendritic cells in cross-presentation is not dictated by antigen capture. Proc. Natl Acad. Sci. USA103(28),10729–10734 (2006).
  Medline CASGoogle Scholar
• 49  Henri S, Poulin LF, Tamoutounour S et al. CD207⁺ CD103⁺ dermal dendritic cells cross-present keratinocyte-derived antigens irrespective of the presence of Langerhans cells. J. Exp. Med.207(1),189–206 (2010).
  Medline CASGoogle Scholar
• 50  del Rio ML, Rodriguez-Barbosa JI, Kremmer E, Forster R. CD103^- and CD103⁺ bronchial lymph node dendritic cells are specialized in presenting and cross-presenting innocuous antigen to CD4⁺ and CD8⁺ T cells. J. Immunol.178(11),6861–6866 (2007).
  Medline CASGoogle Scholar
• 51  Li Y, Wang LX, Pang P et al. Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy. Clin. Cancer Res.17(22),7047–7057 (2011).
  Medline CASGoogle Scholar
• 52  Zou W, Machelon V, Coulomb-L’Hermin A et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat. Med.7(12),1339–1346 (2001).
  Medline CASGoogle Scholar
• 53  Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat. Rev. Immunol.2(3),151–161 (2002).
  Medline CASGoogle Scholar
• 54  Kushwah R, Hu J. Role of dendritic cells in the induction of regulatory T cells. Cell Biosci.1(1),20 (2011).
  Medline CASGoogle Scholar
• 55  Karsunky H, Merad M, Cozzio A, Weissman IL, Manz MG. Flt3 ligand regulates dendritic cell development from Flt3⁺ lymphoid and myeloid-committed progenitors to Flt3⁺ dendritic cells in vivo. J. Exp. Med.198(2),305–313 (2003).
  Medline CASGoogle Scholar
• 56  Schmid MA, Kingston D, Boddupalli S, Manz MG. Instructive cytokine signals in dendritic cell lineage commitment. Immunol. Rev.234(1),32–44 (2010).
  Medline CASGoogle Scholar
• 57  Waskow C, Liu K, Darrasse-Jeze G et al. The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat. Immunol.9(6),676–683 (2008).
  Medline CASGoogle Scholar
• 58  D’Amico A, Wu L. The early progenitors of mouse dendritic cells and plasmacytoid predendritic cells are within the bone marrow hemopoietic precursors expressing Flt3. J. Exp. Med.198(2),293–303 (2003).
  MedlineGoogle Scholar
• 59  Liu K, Nussenzweig MC. Origin and development of dendritic cells. Immunol. Rev.234(1),45–54 (2010).
  Medline CASGoogle Scholar
• 60  Kushwah R, Hu J. Complexity of dendritic cell subsets and their function in the host immune system. Immunology133(4),409–419 (2011).
  Medline CASGoogle Scholar
• 61  Cella M, Jarrossay D, Facchetti F et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med.5(8),919–923 (1999).
  Medline CASGoogle Scholar
• 62  Grouard G, Rissoan MC, Filgueira L, Durand I, Banchereau J, Liu YJ. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J. Exp. Med.185(6),1101–1111 (1997).
  Medline CASGoogle Scholar
• 63  Brawand P, Fitzpatrick DR, Greenfield BW, Brasel K, Maliszewski CR, De Smedt T. Murine plasmacytoid pre-dendritic cells generated from Flt3 ligand-supplemented bone marrow cultures are immature APCs. J. Immunol.169(12),6711–6719 (2002).
  Medline CASGoogle Scholar
• 64  Rissoan MC, Soumelis V, Kadowaki N et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science283(5405),1183–1186 (1999).
  Medline CASGoogle Scholar
• 65  Ito T, Amakawa R, Inaba M, Ikehara S, Inaba K, Fukuhara S. Differential regulation of human blood dendritic cell subsets by IFNs. J. Immunol.166(5),2961–2969 (2001).
  Medline CASGoogle Scholar
• 66  Matta BM, Castellaneta A, Thomson AW. Tolerogenic plasmacytoid DC. Eur. J. Immunol.40(10),2667–2676 (2010).
  Medline CASGoogle Scholar
• 67  Gerlini G, Urso C, Mariotti G et al. Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes. Clin. Immunol.125(2),184–193 (2007).
  Medline CASGoogle Scholar
• 68  Watkins SK, Zhu Z, Riboldi E et al. FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J. Clin. Invest.121(4),1361–1372 (2011).
  MedlineGoogle Scholar
• 69  Bronte V. Tolerogenic pDCs: spotlight on Foxo3. J. Clin. Invest.121(4),1247–1250 (2011).
  Medline CASGoogle Scholar
• 70  Zuniga EI, McGavern DB, Pruneda-Paz JL, Teng C, Oldstone MB. Bone marrow plasmacytoid dendritic cells can differentiate into myeloid dendritic cells upon virus infection. Nat. Immunol.5(12),1227–1234 (2004).
  Medline CASGoogle Scholar
• 71  Soumelis V, Liu YJ. From plasmacytoid to dendritic cell: morphological and functional switches during plasmacytoid pre-dendritic cell differentiation. Eur. J. Immunol.36(9),2286–2292 (2006).
  Medline CASGoogle Scholar
• 72  Krug A, Towarowski A, Britsch S et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur. J. Immunol.31(10),3026–3037 (2001).
  Medline CASGoogle Scholar
• 73  Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Annu. Rev. Immunol.18,767–811 (2000).
  Medline CASGoogle Scholar
• 74  Wolf CE, Meyer M, Riggert J. Leukapheresis for the extraction of monocytes and various lymphocyte subpopulations from peripheral blood: product quality and prediction of the yield using different harvest procedures. Vox Sang.88(4),249–255 (2005).
  Medline CASGoogle Scholar
• 75  Hornung V, Rothenfusser S, Britsch S et al. Quantitative expression of toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol.168(9),4531–4537 (2002).
  Medline CASGoogle Scholar
• 76  Flacher V, Sparber F, Tripp CH, Romani N, Stoitzner P. Targeting of epidermal Langerhans cells with antigenic proteins: attempts to harness their properties for immunotherapy. Cancer Immunol. Immunother.58(7),1137–1147 (2009).
  Medline CASGoogle Scholar
• 77  Ratzinger G, Baggers J, de Cos MA et al. Mature human Langerhans cells derived from CD34⁺ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocyte-derived dendritic cells. J. Immunol.173(4),2780–2791 (2004).
  Medline CASGoogle Scholar
• 78  Santegoets SJ, Bontkes HJ, Stam AG et al. Inducing antitumor T cell immunity: comparative functional analysis of interstitial versus Langerhans dendritic cells in a human cell line model. J. Immunol.180(7),4540–4549 (2008).
  Medline CASGoogle Scholar
• 79  Romano E, Rossi M, Ratzinger G et al. Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. Clin. Cancer Res.17(7),1984–1997 (2011).
  Medline CASGoogle Scholar
• 80  Aspord C, Charles J, Leccia MT et al. A novel cancer vaccine strategy based on HLA-A*0201 matched allogeneic plasmacytoid dendritic cells. PLoS One5(5),E10458 (2010).▪ Uniquely examined the possibility of using plasmacytoid DCs (pDCs) as part of a vaccine construct, and both in vitro assays as well as in vivo testing in a mouse model demonstrated the ability of pDCs to sensitize T cells to elicit an antigen-specific response. The findings of this study indicate the potential for pDCs to be applied successfully as part of DC-based anticancer vaccines.
  MedlineGoogle Scholar
• 81  Chen W, Zhang Z, Shi M et al. Activated plasmacytoid dendritic cells act synergistically with hepatitis B core antigen-pulsed monocyte-derived dendritic cells in the induction of hepatitis B virus-specific CD8 T-cell response. Clin. Immunol.129(2),295–303 (2008).
  Medline CASGoogle Scholar
• 82  Sallusto F, Schaerli P, Loetscher P et al. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur. J. Immunol.28(9),2760–2769 (1998).
  Medline CASGoogle Scholar
• 83  Caux C, Vanbervliet B, Massacrier C et al. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J. Exp. Med.180(5),1841–1847 (1994).
  Medline CASGoogle Scholar
• 84  McLellan AD, Starling GC, Williams LA, Hock BD, Hart DN. Activation of human peripheral blood dendritic cells induces the CD86 co-stimulatory molecule. Eur. J. Immunol.25(7),2064–2068 (1995).
  Medline CASGoogle Scholar
• 85  Albert ML, Jegathesan M, Darnell RB. Dendritic cell maturation is required for the cross-tolerization of CD8⁺ T cells. Nat. Immunol.2(11),1010–1017 (2001).
  Medline CASGoogle Scholar
• 86  Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med.192(9),1213–1222 (2000).
  Medline CASGoogle Scholar
• 87  Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med.193(2),233–238 (2001).
  Medline CASGoogle Scholar
• 88  Jonuleit H, Schmitt E, Steinbrink K, Enk AH. Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol.22(7),394–400 (2001).
  Medline CASGoogle Scholar
• 89  Tan PH, Yates JB, Xue SA et al. Creation of tolerogenic human dendritic cells via intracellular CTLA4: a novel strategy with potential in clinical immunosuppression. Blood106(9),2936–2943 (2005).
  Medline CASGoogle Scholar
• 90  Arce F, Breckpot K, Stephenson H et al. Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis. Arthritis Rheum.63(1),84–95 (2011).
  Medline CASGoogle Scholar
• 91  Perona-Wright G, Anderton SM, Howie SE, Gray D. IL-10 permits transient activation of dendritic cells to tolerize T cells and protect from central nervous system autoimmune disease. Int. Immunol.19(9),1123–1134 (2007).
  Medline CASGoogle Scholar
• 92  Loscher CE, Draper E, Leavy O, Kelleher D, Mills KH, Roche HM. Conjugated linoleic acid suppresses NF-κ B activation and IL-12 production in dendritic cells through ERK-mediated IL-10 induction. J. Immunol.175(8),4990–4998 (2005).
  Medline CASGoogle Scholar
• 93  Banerjee DK, Dhodapkar MV, Matayeva E, Steinman RM, Dhodapkar KM. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood108(8),2655–2661 (2006).
  Medline CASGoogle Scholar
• 94  Mahnke K, Johnson TS, Ring S, Enk AH. Tolerogenic dendritic cells and regulatory T cells: a two-way relationship. J. Dermatol. Sci.46(3),159–167 (2007).
  Medline CASGoogle Scholar
• 95  Almand B, Clark JI, Nikitina E et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol.166(1),678–689 (2001).
  Medline CASGoogle Scholar
• 96  Gabrilovich D, Ishida T, Oyama T et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood92(11),4150–4166 (1998).
  Medline CASGoogle Scholar
• 97  Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen-specific inhibition of CD8⁺ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol.172(2),989–999 (2004).
  Medline CASGoogle Scholar
• 98  Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol.16(1),53–65 (2006).
  Medline CASGoogle Scholar
• 99  Thomas DA, Massague J. TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell8(5),369–380 (2005).
  Medline CASGoogle Scholar
• 100  Valenti R, Huber V, Filipazzi P et al. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-β-mediated suppressive activity on T lymphocytes. Cancer Res.66(18),9290–9298 (2006).
  Medline CASGoogle Scholar
• 101  Loercher AE, Nash MA, Kavanagh JJ, Platsoucas CD, Freedman RS. Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J. Immunol.163(11),6251–6260 (1999).
  Medline CASGoogle Scholar
• 102  Filipazzi P, Valenti R, Huber V et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol.25(18),2546–2553 (2007).
  Medline CASGoogle Scholar
• 103  Peranzoni E, Zilio S, Marigo I et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin Immunol.22(2),238–244 (2010).
  Medline CASGoogle Scholar
• 104  Ribechini E, Greifenberg V, Sandwick S, Lutz MB. Subsets, expansion and activation of myeloid-derived suppressor cells. Med. Microbiol. Immunol.199(3),273–281 (2010).
  Medline CASGoogle Scholar
• 105  Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells in human cancer. Cancer J.16(4),348–353 (2010).
  Medline CASGoogle Scholar
• 106  Vuk-Pavlovic S, Bulur PA, Lin Y et al. Immunosuppressive CD14⁺HLA-DRlow/- monocytes in prostate cancer. Prostate70(4),443–455 (2010).
  Medline CASGoogle Scholar
• 107  Awasthi A, Carrier Y, Peron JP et al. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat. Immunol.8(12),1380–1389 (2007).
  Medline CASGoogle Scholar
• 108  Lan Q, Zhou X, Fan H et al. Polyclonal CD4⁺Foxp3⁺ Treg cells induce TGFβ-dependent tolerogenic dendritic cells that suppress murine lupus-like syndrome. J. Mol. Cell. Biol. doi:10.1093/jmcb/mjs040 (2012) (Epub ahead of print).
  Google Scholar
• 109  Pallotta MT, Orabona C, Volpi C et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat. Immunol.12(9),870–878 (2011).
  Medline CASGoogle Scholar
• 110  Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4⁺CD25⁺ regulatory T cells. Nat. Immunol.4(4),330–336 (2003).
  Medline CASGoogle Scholar
• 111  Qin S, Cobbold SP, Pope H et al. “Infectious” transplantation tolerance. Science259(5097),974–977 (1993).
  Medline CASGoogle Scholar
• 112  Cobbold SP. Future therapeutics for the induction of peripheral immune tolerance in autoimmune disease and organ transplantation. Immunotherapy1(3),447–460 (2009).
  CASGoogle Scholar
• 113  Schmieder A, Michel J, Schonhaar K, Goerdt S, Schledzewski K. Differentiation and gene expression profile of tumor-associated macrophages. Semin. Cancer Biol.22(4),289–297 (2012).
  Medline CASGoogle Scholar
• 114  Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol.25,267–296 (2007).
  Medline CASGoogle Scholar
• 115  Pulendran B, Smith JL, Jenkins M, Schoenborn M, Maraskovsky E, Maliszewski CR. Prevention of peripheral tolerance by a dendritic cell growth factor: flt3 ligand as an adjuvant. J. Exp. Med.188(11),2075–2082 (1998).
  Medline CASGoogle Scholar
• 116  Gong J, Chen D, Kashiwaba M et al. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc. Natl Acad. Sci. USA95(11),6279–6283 (1998).
  Medline CASGoogle Scholar
• 117  Steptoe RJ, Fu F, Li W et al. Augmentation of dendritic cells in murine organ donors by Flt3 ligand alters the balance between transplant tolerance and immunity. J. Immunol.159(11),5483–5491 (1997).
  Medline CASGoogle Scholar
• 118  Bronte V, Apolloni E, Cabrelle A et al. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood96(12),3838–3846 (2000).
  Medline CASGoogle Scholar
• 119  Terabe M, Shimizu M, Mabuchi A et al. Unresponsiveness of intrahepatic lymphocytes to bacterial superantigen: rapid development of suppressive Mac-1(high) cells in the mouse liver. Hepatology32(3),507–513 (2000).
  Medline CASGoogle Scholar
• 120  Fiorucci S, Santucci L, Gresele P, Faccino RM, Del Soldato P, Morelli A. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology124(3),600–607 (2003).
  Medline CASGoogle Scholar
• 121  De Santo C, Serafini P, Marigo I et al. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc. Natl Acad. Sci. USA102(11),4185–4190 (2005).
  Medline CASGoogle Scholar
• 122  Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med.179(4),1109–1118 (1994).
  Medline CASGoogle Scholar
• 123  Czerniecki BJ, Carter C, Rivoltini L et al. Calcium ionophore-treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells. J. Immunol.159(8),3823–3837 (1997).
  Medline CASGoogle Scholar
• 124  Dauer M, Obermaier B, Herten J et al. Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J. Immunol.170(8),4069–4076 (2003).
  Medline CASGoogle Scholar
• 125  Lyakh LA, Koski GK, Telford W, Gress RE, Cohen PA, Rice NR. Bacterial lipopolysaccharide, TNF-α, and calcium ionophore under serum-free conditions promote rapid dendritic cell-like differentiation in CD14⁺ monocytes through distinct pathways that activate NK-κB. J. Immunol.165(7),3647–3655 (2000).
  Medline CASGoogle Scholar
• 126  Koski GK, Lyakh LA, Rice NR. Rapid lipopolysaccharide-induced differentiation of CD14(+) monocytes into CD83(+) dendritic cells is modulated under serum-free conditions by exogenously added IFN-γ and endogenously produced IL-10. Eur. J. Immunol.31(12),3773–3781 (2001).
  Medline CASGoogle Scholar
• 127  Vanderlocht J, Van Elssen CH, Senden-Gijsbers BL et al. Increased tumor-specific CD8⁺ T cell induction by dendritic cells matured with a clinical grade TLR-agonist in combination with IFN-γ. Int. J. Immunopathol. Pharmacol.23(1),35–50 (2010).
  Medline CASGoogle Scholar
• 128  Breckpot K, Escors D. Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification. Endocr. Metab. Immune Disord. Drug Targets9(4),328–343 (2009).▪ Emphasizes the importance of DC activation state when developing DC-based vaccines and reviews the importance of Toll-like receptor (TLR) pathways in activating DCs. Furthermore, genetic modification to take advantage of activation pathways and the potential therapeutic role of this technology is addressed, with various strategies being reviewed.
  Medline CASGoogle Scholar
• 129  Bonehill A, Tuyaerts S, Van Nuffel AM et al. Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol. Ther. J. Am. Soc. Gene Ther.16(6),1170–1180 (2008).▪▪ Demonstrates successful enhancement of the ability of DCs to stimulate antigen-specific T-cell responses, a necessary component of DC-based vaccines, by genetically modifying DCs to take advantage of known stimulatory pathways. These results support genetically engineering DCs as a potential method for overcoming immune tolerance and improving the success of DC-based vaccines.
  Medline CASGoogle Scholar
• 130  Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol.136(7),2348–2357 (1986).
  Medline CASGoogle Scholar
• 131  O’Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity8(3),275–283 (1998).
  MedlineGoogle Scholar
• 132  Seder RA, Paul WE. Acquisition of lymphokine-producing phenotype by CD4⁺ T cells. Annu. Rev. Immunol.12,635–673 (1994).
  Medline CASGoogle Scholar
• 133  Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature383(6603),787–793 (1996).
  Medline CASGoogle Scholar
• 134  O’Garra A, Murphy K. T-cell subsets in autoimmunity. Curr. Opin Immunol.5(6),880–886 (1993).
  MedlineGoogle Scholar
• 135  Liblau RS, Singer SM, McDevitt HO. Th1 and Th2 CD4⁺ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol. Today16(1),34–38 (1995).
  Medline CASGoogle Scholar
• 136  Nishimura T, Iwakabe K, Sekimoto M et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J. Exp. Med.190(5),617–627 (1999).
  Medline CASGoogle Scholar
• 137  Ji Y, Zhang W. Th17 cells: positive or negative role in tumor? Cancer Immunol. Immunother.59(7),979–987 (2010).
  MedlineGoogle Scholar
• 138  Nishimura T, Nakui M, Sato M et al. The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother. Pharmacol.46(Suppl.) S52–S61 (2000).
  Medline CASGoogle Scholar
• 139  Czerniecki BJ, Roses RE, Koski GK. Development of vaccines for high-risk ductal carcinoma in situ of the breast. Cancer Res.67(14),6531–6534 (2007).
  Medline CASGoogle Scholar
• 140  Feili-Hariri M, Falkner DH, Morel PA. Polarization of naive T cells into Th1 or Th2 by distinct cytokine-driven murine dendritic cell populations: implications for immunotherapy. J. Leukoc. Biol.78(3),656–664 (2005).
  Medline CASGoogle Scholar
• 141  Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol.6(8),769–776 (2005).
  Medline CASGoogle Scholar
• 142  de Jong EC, Vieira PL, Kalinski P et al. Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse th cell-polarizing signals. J. Immunol.168(4),1704–1709 (2002).
  Medline CASGoogle Scholar
• 143  Snijders A, Kalinski P, Hilkens CM, Kapsenberg ML. High-level IL-12 production by human dendritic cells requires two signals. Int. Immunol.10(11),1593–1598 (1998).
  Medline CASGoogle Scholar
• 144  Xu S, Koski GK, Faries M et al. Rapid high efficiency sensitization of CD8⁺ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J. Immunol.171(5),2251–2261 (2003).
  Medline CASGoogle Scholar
• 145  Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol.13,251–276 (1995).
  Medline CASGoogle Scholar
• 146  Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O’Garra A, Murphy KM. Development of TH1 CD4⁺ T cells through IL-12 produced by Listeria-induced macrophages. Science260(5107),547–549 (1993).
  Medline CASGoogle Scholar
• 147  Kobayashi M, Fitz L, Ryan M et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med.170(3),827–845 (1989).
  Medline CASGoogle Scholar
• 148  Moser M, Murphy KM. Dendritic cell regulation of TH1-TH2 development. Nat. Immunol.1(3),199–205 (2000).
  Medline CASGoogle Scholar
• 149  Heufler C, Koch F, Stanzl U et al. Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-γ production by T helper 1 cells. Eur. J. Immunol.26(3),659–668 (1996).
  Medline CASGoogle Scholar
• 150  Voest EE, Kenyon BM, O’Reilly MS, Truitt G, D’Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J. Natl Cancer Inst.87(8),581–586 (1995).
  Medline CASGoogle Scholar
• 151  Chan SH, Perussia B, Gupta JW et al. Induction of interferon γ production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J. Exp. Med.173(4),869–879 (1991).
  Medline CASGoogle Scholar
• 152  Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev.13(2),155–168 (2002).
  Medline CASGoogle Scholar
• 153  Dhodapkar MV, Young JW, Chapman PB et al. Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients. Clin. Cancer Res.6(12),4831–4838 (2000).
  Medline CASGoogle Scholar
• 154  Yang S, Linette GP, Longerich S, Haluska FG. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity. J. Immunol.169(1),531–539 (2002).
  Medline CASGoogle Scholar
• 155  Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res.58(21),4902–4908 (1998).
  Medline CASGoogle Scholar
• 156  Czerniecki BJ, Koski GK, Koldovsky U et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res.67(4),1842–1852 (2007).
  Medline CASGoogle Scholar
• 157  Sharma A, Koldovsky U, Xu S et al. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer118(17),4354–4362 (2012).▪▪ A clinical trial of a DC-based vaccine applied in early-stage cancer with promising preliminary clinical results. This trial reflects and supports a shift towards administering cancer vaccines in earlier stage disease. Another unique aspect of this trial was the use of DC1-phenotype matured with TLR agonists in contrast to the more classically employed cytokine-matured DCs.
  Medline CASGoogle Scholar
• 158  Muranski P, Restifo NP. Does IL-17 promote tumor growth? Blood114(2),231–232 (2009).
  Medline CASGoogle Scholar
• 159  Mattes J, Hulett M, Xie W et al. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J. Exp. Med.197(3),387–393 (2003).
  Medline CASGoogle Scholar
• 160  Dunn GP, Bruce AT, Sheehan KC et al. A critical function for type I interferons in cancer immunoediting. Nat. Immunol.6(7),722–729 (2005).
  Medline CASGoogle Scholar
• 161  Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol.6(11),836–848 (2006).
  Medline CASGoogle Scholar
• 162  Aspord C, Pedroza-Gonzalez A, Gallegos M et al. Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4⁺ T cells that facilitate tumor development. J. Exp. Med.204(5),1037–1047 (2007).
  Medline CASGoogle Scholar
• 163  DeNardo DG, Barreto JB, Andreu P et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell16(2),91–102 (2009).
  Medline CASGoogle Scholar
• 164  Harrington LE, Hatton RD, Mangan PR et al. Interleukin 17-producing CD4⁺ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol.6(11),1123–1132 (2005).
  Medline CASGoogle Scholar
• 165  Langrish CL, Chen Y, Blumenschein WM et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med.201(2),233–240 (2005).
  Medline CASGoogle Scholar
• 166  McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway. Trends Immunol.27(1),17–23 (2006).
  Medline CASGoogle Scholar
• 167  Roses RE, Xu S, Xu M, Koldovsky U, Koski G, Czerniecki BJ. Differential production of IL-23 and IL-12 by myeloid-derived dendritic cells in response to TLR agonists. J. Immunol.181(7),5120–5127 (2008).▪ Elucidates signals that induce a DC17 phenotype and also demonstrates the ability to prime T cells using DC1s and DC17s to elicit Th1- and Th17-polarized antigen-specific responses, respectively. These findings lay groundwork for conducting further testing of the role of the Th17 response in cancer immunity.
  Medline CASGoogle Scholar
• 168  Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol.8(9),942–949 (2007).
  Medline CASGoogle Scholar
• 169  Langowski JL, Zhang X, Wu L et al. IL-23 promotes tumour incidence and growth. Nature442(7101),461–465 (2006).
  Medline CASGoogle Scholar
• 170  Kryczek I, Wei S, Zou L et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J. Immunol.178(11),6730–6733 (2007).
  Medline CASGoogle Scholar
• 171  Sfanos KS, Bruno TC, Maris CH et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin. Cancer Res.14(11),3254–3261 (2008).
  Medline CASGoogle Scholar
• 172  Kryczek I, Banerjee M, Cheng P et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood114(6),1141–1149 (2009).
  Medline CASGoogle Scholar
• 173  Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin’s lymphoma. Cancer Res.69(13),5522–5530 (2009).
  Medline CASGoogle Scholar
• 174  Horlock C, Stott B, Dyson PJ et al. The effects of trastuzumab on the CD4⁺CD25⁺FoxP3⁺ and CD4⁺IL17A⁺ T-cell axis in patients with breast cancer. Br. J. Cancer100(7),1061–1067 (2009).
  Medline CASGoogle Scholar
• 175  Numasaki M, Fukushi J, Ono M et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood101(7),2620–2627 (2003).
  Medline CASGoogle Scholar
• 176  Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol.7(1),41–51 (2007).
  Medline CASGoogle Scholar
• 177  Takahashi H, Numasaki M, Lotze MT, Sasaki H. Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells. Immunol. Lett.98(2),189–193 (2005).
  Medline CASGoogle Scholar
• 178  Inozume T, Hanada K, Wang QJ, Yang JC. IL-17 secreted by tumor reactive T cells induces IL-8 release by human renal cancer cells. J. Immunother.32(2),109–117 (2009).
  Medline CASGoogle Scholar
• 179  Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest.117(5),1175–1183 (2007).
  Medline CASGoogle Scholar
• 180  Zhang Q, Liu S, Ge D et al. Interleukin-17 promotes formation and growth of prostate adenocarcinoma in mouse models. Cancer Res.72(10),2589–2599 (2012).
  Medline CASGoogle Scholar
• 181  Benchetrit F, Ciree A, Vives V et al. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood99(6),2114–2121 (2002).
  Medline CASGoogle Scholar
• 182  Kortylewski M, Kujawski M, Wang T et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med.11(12),1314–1321 (2005).
  Medline CASGoogle Scholar
• 183  Overwijk WW, de Visser KE, Tirion FH et al. Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J. Immunol.176(9),5213–5222 (2006).
  Medline CASGoogle Scholar
• 184  Kaiga T, Sato M, Kaneda H, Iwakura Y, Takayama T, Tahara H. Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12. J. Immunol.178(12),7571–7580 (2007).
  Medline CASGoogle Scholar
• 185  Lo CH, Lee SC, Wu PY et al. Antitumor and antimetastatic activity of IL-23. J. Immunol.171(2),600–607 (2003).
  Medline CASGoogle Scholar
• 186  Hu J, Yuan X, Belladonna ML et al. Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res.66(17),8887–8896 (2006).
  Medline CASGoogle Scholar
• 187  Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat. Immunol.8(4),345–350 (2007).
  Medline CASGoogle Scholar
• 188  Muranski P, Boni A, Antony PA et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood112(2),362–373 (2008).
  Medline CASGoogle Scholar
• 189  Lee YK, Turner H, Maynard CL et al. Late developmental plasticity in the T helper 17 lineage. Immunity30(1),92–107 (2009).
  Medline CASGoogle Scholar
• 190  Suryani S, Sutton I. An interferon-γ-producing Th1 subset is the major source of IL-17 in experimental autoimmune encephalitis. J. Neuroimmunol.183(1–2),96–103 (2007).
  Medline CASGoogle Scholar
• 191  Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother.54(8),721–728 (2005).
  Medline CASGoogle Scholar
• 192  Bonehill A, Heirman C, Thielemans K. Genetic approaches for the induction of a CD4⁺ T cell response in cancer immunotherapy. J. Gene Med.7(6),686–695 (2005).
  Medline CASGoogle Scholar
• 193  Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med.4(3),328–332 (1998).
  Medline CASGoogle Scholar
• 194  Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med.4(3),321–327 (1998).
  Medline CASGoogle Scholar
• 195  Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA90(8),3539–3543 (1993).
  Medline CASGoogle Scholar
• 196  Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J. Exp. Med.188(12),2357–2368 (1998).
  Medline CASGoogle Scholar
• 197  Schattner EJ, Mascarenhas J, Bishop J et al. CD4⁺ T-cell induction of Fas-mediated apoptosis in Burkitt’s lymphoma B cells. Blood88(4),1375–1382 (1996).
  Medline CASGoogle Scholar
• 198  Thomas WD, Hersey P. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J. Immunol.161(5),2195–2200 (1998).
  Medline CASGoogle Scholar
• 199  Echchakir H, Bagot M, Dorothee G et al. Cutaneous T cell lymphoma reactive CD4⁺ cytotoxic T lymphocyte clones display a Th1 cytokine profile and use a fas-independent pathway for specific tumor cell lysis. J. Invest. Dermatol.115(1),74–80 (2000).
  Medline CASGoogle Scholar
• 200  Kang TW, Yevsa T, Woller N et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature479(7374),547–551 (2011).
  Medline CASGoogle Scholar
• 201  Rakhra K, Bachireddy P, Zabuawala T et al. CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell18(5),485–498 (2010).
  Medline CASGoogle Scholar
• 202  Janssen EM, Droin NM, Lemmens EE et al. CD4⁺ T-cell help controls CD8⁺ T-cell memory via TRAIL-mediated activation-induced cell death. Nat.434(7029),88–93 (2005).
  CASGoogle Scholar
• 203  Marzo AL, Kinnear BF, Lake RA et al. Tumor-specific CD4⁺ T cells have a major “post-licensing” role in CTL mediated anti-tumor immunity. J. Immunol.165(11),6047–6055 (2000).
  Medline CASGoogle Scholar
• 204  Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4⁺ T cells are required for secondary expansion and memory in CD8⁺ T lymphocytes. Nature421(6925),852–856 (2003).
  Medline CASGoogle Scholar
• 205  Cui W, Kaech SM. Generation of effector CD8⁺ T cells and their conversion to memory T cells. Immunol. Rev.236,151–166 (2010).
  Medline CASGoogle Scholar
• 206  Bourgeois C, Rocha B, Tanchot C. A role for CD40 expression on CD8⁺ T cells in the generation of CD8⁺ T cell memory. Science297(5589),2060–2063 (2002).
  Medline CASGoogle Scholar
• 207  Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science300(5617),337–339 (2003).
  Medline CASGoogle Scholar
• 208  Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4⁺ T-helper and a T-killer cell. Nature393(6684),474–478 (1998).
  Medline CASGoogle Scholar
• 209  Sornasse T, Flamand V, De Becker G et al. Antigen-pulsed dendritic cells can efficiently induce an antibody response in vivo. J. Exp. Med.175(1),15–21 (1992).
  Medline CASGoogle Scholar
• 210  Gonzalez-Martin A, Gomez L, Lustgarten J, Mira E, Manes S. Maximal T cell-mediated antitumor responses rely upon CCR5 expression in both CD4(+) and CD8(+) T cells. Cancer Res.71(16),5455–5466 (2011).
  Medline CASGoogle Scholar
• 211  Takemoto S, Nishikawa M, Guan X, Ohno Y, Yata T, Takakura Y. Enhanced generation of cytotoxic T lymphocytes by heat shock protein 70 fusion proteins harboring both CD8(+) T cell and CD4(+) T cell epitopes. Mol. Pharm.7(5),1715–1723 (2010).
  Medline CASGoogle Scholar
• 212  Van Nuffel AM, Benteyn D, Wilgenhof S et al. Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4⁺ and CD8⁺ T cells in melanoma patients. Mol. Ther.20(5),1063–1074 (2012).
  Medline CASGoogle Scholar
• 213  Koski GK, Koldovsky U, Xu S et al. A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J. Immunother.35(1),54–65 (2012).
  Medline CASGoogle Scholar
• 214  Gok M, Ozcerit AT. Prediction of MHC class I binding peptides with a new feature encoding technique. Cell Immunol.275(1–2),1–4 (2012).
  Medline CASGoogle Scholar
• 215  Chaves FA, Lee AH, Nayak JL, Richards KA, Sant AJ. The utility and limitations of current web-available algorithms to predict peptides recognized by CD4 T cells in response to pathogen infection. J. Immunol.188(9),4235–4248 (2012).
  Medline CASGoogle Scholar
• 216  Lin HH, Ray S, Tongchusak S, Reinherz EL, Brusic V. Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research. BMC Immunol.9,8 (2008).
  MedlineGoogle Scholar
• 217  Chen JL, Stewart-Jones G, Bossi G et al. Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J. Exp. Med.201(8),1243–1255 (2005).
  Medline CASGoogle Scholar
• 218  Liao WW, Arthur JW. Predicting peptide binding to major histocompatibility complex molecules. Autoimmun. Rev.10(8),469–473 (2011).
  Medline CASGoogle Scholar
• 219  Lin HH, Zhang GL, Tongchusak S, Reinherz EL, Brusic V. Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research. BMC Bioinformatics9(Suppl. 12),S22 (2008).
  MedlineGoogle Scholar
• 220  Wang P, Sidney J, Dow C, Mothe B, Sette A, Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput. Biol.4(4),E1000048 (2008).
  MedlineGoogle Scholar
• 221  Kawashima I, Hudson SJ, Tsai V et al. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum. Immunol.59(1),1–14 (1998).
  Medline CASGoogle Scholar
• 222  Kovjazin R, Volovitz I, Kundel Y et al. ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors. Vaccine29(29–30),4676–4686 (2011).
  Medline CASGoogle Scholar
• 223  Kosmrlj A, Read EL, Qi Y et al. Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection. Nature465(7296),350–354 (2010).
  Medline CASGoogle Scholar
• 224  Rosenberg SA, Zhai Y, Yang JC et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J. Natl Cancer Inst.90(24),1894–1900 (1998).
  Medline CASGoogle Scholar
• 225  Shahabi V, Seavey MM, Maciag PC, Rivera S, Wallecha A. Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human. Cancer Gene Ther.18(1),53–62 (2011).
  Medline CASGoogle Scholar
• 226  Duan XY, Han DG, Zhang MX, Wang JS. Generation of fusion protein EGFRvIII-HBcAg and its anti-tumor effect in vivo. J. Exp. Clin. Cancer Res.28,133 (2009).
  Medline CASGoogle Scholar
• 227  Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin. Cancer Res.17(11),3520–3526 (2011).
  MedlineGoogle Scholar
• 228  Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double-blind, placebo-controlled, Phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer115(16),3670–3679 (2009).
  Medline CASGoogle Scholar
• 229  Rosenthal KS, Taylor P, Zimmerman DH. J-LEAPS peptide and LEAPS dendritic cell vaccines. Microb. Biotechnol.5(2),203–213 (2012).
  Medline CASGoogle Scholar
• 230  Taylor PR, Paustian CC, Koski GK, Zimmerman DH, Rosenthal KS. Maturation of dendritic cell precursors into IL12-producing DCs by J-LEAPS immunogens. Cell. Immunol.262(1),1–5 (2010).
  Medline CASGoogle Scholar
• 231  Taylor PR, Koski GK, Paustian CC et al. J-LEAPS vaccines initiate murine Th1 responses by activating dendritic cells. Vaccine28(34),5533–5542 (2010).
  Medline CASGoogle Scholar
• 232  Buteau C, Markovic SN, Celis E. Challenges in the development of effective peptide vaccines for cancer. Mayo Clinic Proc. Mayo Clin.77(4),339–349 (2002).
  Medline CASGoogle Scholar
• 233  Lee WT, Tan C, Koski G, Shu S, Cohen P. Immunotherapy using allogeneic squamous cell tumor–dendritic cell fusion hybrids. Head Neck32(9),1209–1216 (2010).
  MedlineGoogle Scholar
• 234  Shimizu K, Kuriyama H, Kjaergaard J, Lee W, Tanaka H, Shu S. Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. J. Immunother.27(4),265–272 (2004).
  Medline CASGoogle Scholar
• 235  Kuriyama H, Watanabe S, Kjaergaard J et al. Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination. Cell Immunol.243(1),30–40 (2006).
  Medline CASGoogle Scholar
• 236  Hayashi T, Tanaka H, Tanaka J et al. Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion. Clin. Immunol.104(1),14–20 (2002).
  Medline CASGoogle Scholar
• 237  Kjaergaard J, Shimizu K, Shu S. Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine. Cell. Immunol.225(2),65–74 (2003).
  Medline CASGoogle Scholar
• 238  Parkhurst MR, DePan C, Riley JP, Rosenberg SA, Shu S. Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. J. Immunol.170(10),5317–5325 (2003).
  Medline CASGoogle Scholar
• 239  Zhang Y, Ma B, Zhou Y et al. Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cells. Breast Cancer Res. Treat.105(3),277–286 (2007).
  Medline CASGoogle Scholar
• 240  Zhou J, Weng D, Zhou F et al. Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses. Cancer Immunol. Immunother.58(10),1587–1597 (2009).
  Medline CASGoogle Scholar
• 241  Boudreau JE, Bonehill A, Thielemans K, Wan Y. Engineering dendritic cells to enhance cancer immunotherapy. Mol. Ther. J. Am. Soc. Gene Ther.19(5),841–853 (2011).
  Medline CASGoogle Scholar
• 242  Park MJ, Kim EK, Han JY et al. Fusion of the human cytomegalovirus pp65 antigen with both ubiquitin and ornithine decarboxylase additively enhances antigen presentation to CD8(+) T cells in human dendritic cells. Hum. Gene Ther.21(8),957–967 (2010).
  Medline CASGoogle Scholar
• 243  Wu TC, Guarnieri FG, Staveley-O’Carroll KF et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc. Natl Acad. Sci. USA92(25),11671–11675 (1995).
  Medline CASGoogle Scholar
• 244  Bonehill A, Heirman C, Tuyaerts S et al. Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J. Immunol.172(11),6649–6657 (2004).▪ Illustrates another application of genetically modifying DCs by engineering them to present antigen on both class I and II molecules. Simultaneous presentation addresses the limit of current peptide vaccines that may be unable to activate both CD4+ and CD8+ T cells. This study demonstrates both the feasibility of genetically modifying DCs to simultaneously present antigen on both class I and II molecules and also addresses how to optimize the efficacy of such simultaneous presentation.
  Medline CASGoogle Scholar
• 245  Dullaers M, Breckpot K, Van Meirvenne S et al. Side-by-side comparison of lentivirally transduced and mRNA-electroporated dendritic cells: implications for cancer immunotherapy protocols. Mol. Ther. J. Am. Soc. Gene Ther.10(4),768–779 (2004).
  Medline CASGoogle Scholar
• 246  Coosemans A, Wolfl M, Berneman ZN et al. Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma. Anticancer Res.30(9),3709–3714 (2010).
  MedlineGoogle Scholar
• 247  Van Tendeloo VF, Van de Velde A, Van Driessche A et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination. Proc. Natl Acad. Sci. USA107(31),13824–13829 (2010).
  Medline CASGoogle Scholar
• 248  Kikuchi T, Moore MA, Crystal RG. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood96(1),91–99 (2000).
  Medline CASGoogle Scholar
• 249  Koya RC, Kasahara N, Favaro PM et al. Potent maturation of monocyte-derived dendritic cells after CD40L lentiviral gene delivery. J. Immunother.26(5),451–460 (2003).
  Medline CASGoogle Scholar
• 250  Feder-Mengus C, Schultz-Thater E, Oertli D et al. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4⁺ and CD8⁺ T cell responses. Hum. Gene Ther.16(3),348–360 (2005).
  Medline CASGoogle Scholar
• 251  Tcherepanova IY, Adams MD, Feng X et al. Ectopic expression of a truncated CD40L protein from synthetic post-transcriptionally capped RNA in dendritic cells induces high levels of IL-12 secretion. BMC Mol. Biol.9,90 (2008).
  MedlineGoogle Scholar
• 252  Knippertz I, Hesse A, Schunder T et al. Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-γ. J. Immunother.32(5),524–538 (2009).
  Medline CASGoogle Scholar
• 253  Bonehill A, Van Nuffel AM, Corthals J et al. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin. Cancer Res.15(10),3366–3375 (2009).
  Medline CASGoogle Scholar
• 254  Wiethe C, Debus A, Mohrs M, Steinkasserer A, Lutz M, Gessner A. Dendritic cell differentiation state and their interaction with NKT cells determine Th1/Th2 differentiation in the murine model of Leishmania major infection. J. Immunol.180(7),4371–4381 (2008).
  Medline CASGoogle Scholar
• 255  Dannull J, Nair S, Su Z et al. Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. Blood105(8),3206–3213 (2005).
  Medline CASGoogle Scholar
• 256  Ojima T, Iwahashi M, Nakamura M et al. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Int. J. Oncol.28(4),947–953 (2006).
  Medline CASGoogle Scholar
• 257  Minkis K, Kavanagh DG, Alter G et al. Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells. Cancer Res.68(22),9441–9450 (2008).
  Medline CASGoogle Scholar
• 258  Wang J, Ouyang Y, Guner Y, Ford HR, Grishin AV. Ubiquitin-editing enzyme A20 promotes tolerance to lipopolysaccharide in enterocytes. J. Immunol.183(2),1384–1392 (2009).
  Medline CASGoogle Scholar
• 259  Breckpot K, Aerts-Toegaert C, Heirman C et al. Attenuated expression of A20 markedly increases the efficacy of double-stranded RNA-activated dendritic cells as an anti-cancer vaccine. J. Immunol.182(2),860–870 (2009).
  Medline CASGoogle Scholar
• 260  Song XT, Evel-Kabler K, Shen L, Rollins L, Huang XF, Chen SY. A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat. Med.14(3),258–265 (2008).
  Medline CASGoogle Scholar
• 261  Shen L, Evel-Kabler K, Strube R, Chen SY. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat. Biotechnol.22(12),1546–1553 (2004).
  Medline CASGoogle Scholar
• 262  Shi L, Luo K, Xia D et al. DIgR2, dendritic cell-derived immunoglobulin receptor 2, is one representative of a family of IgSF inhibitory receptors and mediates negative regulation of dendritic cell-initiated antigen-specific T-cell responses. Blood108(8),2678–2686 (2006).
  Medline CASGoogle Scholar
• 263  Gray A, Raff AB, Chiriva-Internati M, Chen SY, Kast WM. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. Immunol. Rev.222,316–327 (2008).
  Medline CASGoogle Scholar
• 264  Roychowdhury S, Talpaz M. Managing resistance in chronic myeloid leukemia. Blood Rev.25(6),279–290 (2011).
  MedlineGoogle Scholar
• 265  Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med.363(9),809–819 (2010).
  Medline CASGoogle Scholar
• 266  Hakim FT, Cepeda R, Kaimei S et al. Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood90(9),3789–3798 (1997).
  Medline CASGoogle Scholar
• 267  Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat. Rev. Drug Discov.11(3),215–233 (2012).
  Medline CASGoogle Scholar
• 268  Simeone E, Ascierto PA. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1. J. Immunotoxicol.9(3),241–247 (2012).
  Medline CASGoogle Scholar
• 269  Garcia-Hernandez Mde L, Gray A, Hubby B, Klinger OJ, Kast WM. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res.68(3),861–869 (2008).
  MedlineGoogle Scholar
• 270  Einstein MH, Kadish AS, Burk RD et al. Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol. Oncol.106(3),453–460 (2007).
  Medline CASGoogle Scholar
• 271  Geiger JD, Hutchinson RJ, Hohenkirk LF et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res.61(23),8513–8519 (2001).
  Medline CASGoogle Scholar
• 272  Jonuleit H, Giesecke-Tuettenberg A, Tuting T et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int. J. Cancer93(2),243–251 (2001).
  Medline CASGoogle Scholar
• 273  Schuler-Thurner B, Schultz ES, Berger TG et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J. Exp. Med.195(10),1279–1288 (2002).
  Medline CASGoogle Scholar
• 274  Lepisto AJ, Moser AJ, Zeh H et al. A Phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther.6(B),955–964 (2008).
  Medline CASGoogle Scholar
• 275  Soleimani A, Berntsen A, Svane IM, Pedersen AE. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate. Scand. J. Immunol.70(5),481–489 (2009).
  Medline CASGoogle Scholar
• 276  Rollig C, Schmidt C, Bornhauser M, Ehninger G, Schmitz M, Auffermann-Gretzinger S. Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells. J. Immunother.34(1),100–106 (2011).
  MedlineGoogle Scholar
• 277  Ardon H, Van Gool S, Lopes IS et al. Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. J. Neurooncol.99(2),261–272 (2010).
  Medline CASGoogle Scholar
• 278  Ellebaek E, Engell-Noerregaard L, Iversen TZ et al. Metastatic melanoma patients treated with dendritic cell vaccination, interleukin-2 and metronomic cyclophosphamide: results from a Phase II trial. Cancer Immunol. Immunother.61(10),1791–1804 (2012).
  Medline CASGoogle Scholar
• 279  Alfaro C, Perez-Gracia JL, Suarez N et al. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients. J. Immunol.187(11),6130–6142 (2011).
  Medline CASGoogle Scholar
• 280  Okada H, Kalinski P, Ueda R et al. Induction of CD8⁺ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {α}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J. Clin. Oncol.29(3),330–336 (2011).
  Medline CASGoogle Scholar
• 281  Banchereau J, Palucka AK, Dhodapkar M et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res.61(17),6451–6458 (2001).
  Medline CASGoogle Scholar